Overview talk regarding the National Cancer Registration Service, where the data comes from and how clinical/cancer management teams may help to ensure accuracy
Top 20 Famous Indian Female Pornstars Name List 2024
YCN Breast Educational Meeting 2015- Cancer Registration data Caroline Brook
1. National Cancer Registration Service
(NCRS): where does the data come
from and how can you help?
Caroline Brook, Head of Cancer Registration,
National Cancer Registration Service - Northern and Yorkshire
30 September 2015
2. National Cancer Registration Service
National Cancer Registration Service (NCRS)
- Single national service formed as part of the transition to Public Health
England (PHE) in 2013 from 8 predecessor cancer registries.
- Sits within the Chief Knowledge Officer (CKO) Directorate
- National Director, Dr Jem Rashbass
- Retained 8 local offices (responsible for local data providers)
- Operates on a single national IT system – Encore
Member of the UKIACR (UK & Ireland Association of Cancer Registries)
Member of European Network (ENCR) and International Association (IACR)
2 Breast Cancer Educational Meeting
7. National Cancer Registration Service
Data Transfer Partnership Agreements (DTPAs)
- NCRS has a signed DTPA with every data provider (mostly Acute Trusts)
which outlines requirements for data provision/access for the purposes of
cancer registration.
Cancer Outcomes and Services Dataset (COSD)
- All data providers to supply data in the standardised COSD format within 25
working days of the end of a month.
- NCIN webpages give all details relating to dataset and data items
http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd
- Core data items and site-specific
7 Breast Cancer Educational Meeting
8. COSD Conformance reporting
- All datasets received by NCRS are logged in and loaded onto Encore.
- These data are then reported directly via the CancerStats system (including
pathology). (Previously a system called COSD Conformance Portal).
- This will include any refreshes of the data up to a point when it is frozen.
- Produces reports based on data submitted directly from Providers (Level 1
and 2 reports).
- Produces reports on finalised registrations after a further period of time
(Level 3 reports).
- Will produce site-specific clinical headline indicators (CHI) during 2015.
- Can request a login from local NCRS team.
https://nww/cancerstats.nhs.uk
8 Breast Cancer Educational Meeting
17. Staging Performance: NCRS NY
17 Breast Cancer Educational Meeting
ICBP Sites 2012 2013 PHOF Sites and Cervix
Breast 92% 93% Breast
Colorectal 87% 91% Colorectal
Lung 91% 93% Lung
Ovary 89% 91% Ovary
Prostate 80% 91% Prostate
87% Kidney
88% Bladder
94% Melanoma
93% Endometrium
88% NHL
97% Cervix
18. Breast staging: Q1 2014 by CCG
18 Breast Cancer Educational Meeting
(work on-going –not final position)
19. Current targets
- 2013 registrations were completed at the end of January 2015 with PHOF
sites (+ cervix) staged at 81% for England.
- Over half way through processing of 2014 data and will aim to stage all
stageable tumours and finalise by 31 December 2015.
- Have commenced near real-time processing of 2015 data, January – April
processed for whole of England. This will allow a large proportion of the
data to be available sooner for analysis (with appropriate caveats, i.e.
incomplete staging and treatment). We’re just beginning to look at this.
19 Breast Cancer Educational Meeting
20. Whose responsibility?
Data providers have a responsibility to supply timely, accurate and complete
cancer data. (Ideally with at least 70%+ staging.)
BUT…
…in partnership with NCRS, who will help to monitor and provide
feedback/advice in order to continually improve the data.
The better the data coming into NCRS, the more opportunity NCRS will have to
further improve timeliness and also concentrate on more complex data
quality improvement projects, such as working with clinical teams to identify
and code rarer cancers in a more meaningful way.
20 Breast Cancer Educational Meeting
21. How can you help?
- points for consideration.
Do you get involved in collecting/coding data within the MDT meeting?
Do you carry out any validation of data before it is submitted?
Do you access your clinical system and use your own data, i.e. have
confidence that it is correct leaving the Trust?
Are you familiar with how COSD is collected in your Trust and how it is
submitted to the NCRS and by whom?
21 Breast Cancer Educational Meeting
Clinical interest in the data collection
process always improves accuracy.
Sources of national cancer audit data – some more timely and useful than others.
Nature of audits is changing, where national audit datasets will be collated by NCRS.
Other sources of national data.
National data sources that are due to feed into the process centrally, but not quite there yet.
Local data sources from acute providers. These are the key sources for routine, timely notification and staging.
Would look at the number of diagnosed cases across the Trusts to see if there were any obvious issues.
The patterns of missing data here do not reflect those given in the Level 1 report:
Barnsley: No data received for Mar to Jun but looks as though none loaded
Doncaster: No data received for Jun - subsequent data waiting to be loaded in order
Sheffield: All data received but May onwards still being loaded
Rotherham: No data receive for Jun-Jul but Feb onwards still being loaded
Harrogate and Leeds: Data received but portal snapshot taken on 4th October before all August data could be loaded (i.e. Saturday after Friday deadline)
Level 2 reports are updated twice a month
This is currently accessed directly through remote access.
The fact that the staging data isn’t provided to us does not mean that the NCRS is unable to provide staging data for analysis. Thanks to our relationships with the Trusts we at NCRS NY have been able to secure remote access to all of our Trusts. This enables registration staff to look for missing stage and resolve conflicting data and achieve the higher levels of staging data presented here.
NCRS are working to improve the quality and availability of staging data. For 2012 diagnosis we focussed on the four sites required for the International Cancer Benchmarking Project plus prostate. For 2013 cases which we are currently completing were are making further improvements by concentrating on the sites required for the Public Health Outcomes Framework plus Cervix. These figures show our current position. We are working on a site by site basis and have yet to erach ovary and melanoma cases which explains why their level of staging is lower.
Verity is going to show some of the analyses that have been produced using the 2012 data.